Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AST NYSE:MEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsMENBlackRock MuniEnhanced Fund$12.08$12.01$9.95▼$12.57N/AN/A55,540 shs28,963 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%MENBlackRock MuniEnhanced Fund0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTAsterias Biotherapeutics 0.00N/AN/AN/AMENBlackRock MuniEnhanced Fund 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AMENBlackRock MuniEnhanced Fund$0.584.80%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTAsterias BiotherapeuticsN/AMENBlackRock MuniEnhanced FundN/AInsider OwnershipCompanyInsider OwnershipASTAsterias BiotherapeuticsN/AMENBlackRock MuniEnhanced FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableMENBlackRock MuniEnhanced FundN/AN/AN/ANot OptionableMEN, WCAT, AST, and CLON HeadlinesRecent News About These CompaniesBlackRock Plows $2 Billion Into Momentum Stocks After ElectionNovember 11, 2024 | yahoo.comBlackRock Diversified Equity InstNovember 9, 2024 | morningstar.comMBlackRock Wealth Liqd Envirtly Awr Inv ANovember 6, 2024 | morningstar.comMWorldwide index ETF assets up 24% as BlackRock widens lead over VanguardOctober 31, 2024 | pionline.comPBlackRock Advantage CoreAlpha Bond InstOctober 18, 2024 | morningstar.comMSEBI gives approval to Jio Financial and BlackRock to set up mutual fund businessOctober 6, 2024 | moneycontrol.comBlackRock Equity Dividend Inv ASeptember 4, 2024 | morningstar.comMJudge Grants Class Status in Genworth, BlackRock TDF SuitAugust 19, 2024 | planadviser.comPBlackRock Liquidity TempCash InstlJuly 25, 2024 | morningstar.comMBlackRock Event Driven Equity InstlJuly 24, 2024 | morningstar.comMBlackRock Summit Cash Reserves Inv AJuly 20, 2024 | morningstar.comMBlackRock Global Funds - Euro Corporate Bond Fund (B3FF.MU)May 25, 2024 | finance.yahoo.comEPF told to cut ties with BlackRock as groups ramp up pressure on Anwar on Palestine policyMay 23, 2024 | msn.comBlackrock Global Funds - World Healthscience Fund A2 (0P00000K03)April 28, 2024 | investing.comBlackrock: An Attractive Setup To Buy A Globally Leading FranchiseApril 20, 2024 | seekingalpha.comBlackRock Total Return Fund;KMarch 20, 2024 | wsj.comBlackrock Global Funds - World Technology Fund A2 (0P00000AWU)February 7, 2024 | investing.comBlackRock Global Allocation Fund;Investor ADecember 29, 2023 | wsj.comBlackrock Global Funds - World Energy Fund A2 (0P0000RZ3G)December 23, 2023 | investing.comBlackRock LifePath ESG Index 2050 Inv ANovember 11, 2023 | morningstar.comM Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 20253 AI Infrastructure Stocks Powering the Next Tech RevolutionBy Ryan Hasson | August 8, 20255 Stocks to Buy in August With Tremendous Upside PotentialBy Thomas Hughes | July 31, 2025MEN, WCAT, AST, and CLON Company DescriptionsAsterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.BlackRock MuniEnhanced Fund NYSE:MENBlackRock MuniEnhanced Fund, Inc. operates as a closed-end investment fund. The firm intends to provide shareholders with current income exempt from federal income taxes. It invests in long-term municipal bonds rated investment grade quality at the time of investment and invests primarily in long-term municipal bonds with maturities over the time of investment. The company was founded on March 2, 1989 and is headquartered in Wilmington, DE. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Pulls Back Into a Screaming Buy Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access